Berenberg Bank Reaffirms “Buy” Rating for ANGLE (LON:AGL)

Berenberg Bank reiterated their buy rating on shares of ANGLE (LON:AGLFree Report) in a research report sent to investors on Thursday, Marketbeat reports. Berenberg Bank currently has a GBX 70 ($0.94) price target on the stock.

ANGLE Stock Down 5.6 %

Shares of AGL opened at GBX 8.21 ($0.11) on Thursday. The business’s 50 day moving average is GBX 12.83 and its 200 day moving average is GBX 14.49. The company has a market capitalization of £26.49 million, a PE ratio of -102.68 and a beta of 0.22. ANGLE has a 12-month low of GBX 7.11 ($0.10) and a 12-month high of GBX 37.40 ($0.50). The company has a current ratio of 5.38, a quick ratio of 6.18 and a debt-to-equity ratio of 19.85.

ANGLE Company Profile

(Get Free Report)

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD.

Featured Articles

Receive News & Ratings for ANGLE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANGLE and related companies with MarketBeat.com's FREE daily email newsletter.